Short report: Q fever pneumonia: Are clarithromycin and moxifloxacin alternative treatment only?

American Journal of Tropical Medicine and Hygiene

Volumn 73, Issue 5, 2005, Pages 947-948

  Morovic, Miro ^a  

^a GENERAL HOSPITAL ZADAR   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DOXYCYCLINE; MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; COXIELLA BURNETII; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHUMAN; PNEUMONIA; Q FEVER; RELAPSE; SCHOOL CHILD; SEROLOGY; SIDE EFFECT; TREATMENT OUTCOME; BACTERIAL PNEUMONIA; CHILD; CLINICAL TRIAL; DRUG EFFECT; MICROBIOLOGY; MIDDLE AGED;

COXIELLA BURNETII;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CHILD; CLARITHROMYCIN; COXIELLA BURNETII; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; Q FEVER; QUINOLINES; TREATMENT OUTCOME;

EID: 28044473675     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.73.947     Document Type: Article

References (14)

1. Spelman DW, 1982. Q fever: a study of 111 consecutive cases. Med J Aust 1: 547-553.
2. Dumler JS, 2002. Q fever. Curr Treat Options Infect Dis 4: 437-445.
3. Marrie TJ, 2004. Q fever pneumonia. Curr Opin Infect Dis 17: 137-142.
4. File TM Jr, Tan JS, 2003. International guidelines for the treatment of community-acquired pneumonia in adult: the role of macrolides. Drugs 63: 181-205.
5. Hoeffken D, Talan D, Larsen LS, Peloquin S, Choudri SH, Haverstock D, Jackson P, Church D, 2004. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens. Eur J Clin Microbiol Infect Dis 23: 772-775.
6. Maurin M, Benoliel AM, Bongrand P, Raoult D, 1992. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J Infect Dis 166: 1097-1102.
7. Maurin M, Raoult D, 1993. In vitro susceptibilities of spotted fever group ricketsiae and Coxiella burnetii to clarithromycin. Antimicrob Agents Chemother 37: 2633-2637.
8. Gikas A, Spyridaki I, Psaroulaki A, Kofteridis DP, Tselentis Y, 1998. In vitro susceptibility of Coxiella burnetii to trovafloxacin in comparison with susceptibilities to pefloxacin, ciprofloxacin, ofloxacin, doxycycline, and clarithromycin. Antimicrob Agents Chemother 42: 2747-2748.
9. Rolain J-M, Maurin M, Raoult D, 2001. Baclerioslalic and bactericidal activities of moxifloxacin against Coxiella burnetii. Antimicrob Agents Chemother 45: 301-302.
10. Lever MS, Bewley KR, Dowsett B, Lloyd G, 2004. In vitro susceptibility of Coxiella burnetii to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. Int J Antimicrob Agents 24: 194-196.
11. Gikas A, Kofteridis DP, Manios A, Pediadilis J, Tselentis Y, 2001. Newer macrolides as empiric treatment for acute Q fever infection. Antimicrob Agents Chemother 45: 3644-3646.
12. Dzelalija B, Morovic M, Slankovic S, Vukic L, Dobec M, Dujella J, 1990. Clinical spectrum of rickettsioses in the Zadar area. Lijec Vjesn 112: 102-105.
13. Gikas A, Spyridaki I, Scoulica E, Psaroulaki A, Tselentis Y, 2001. In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin. Antimicrob Agents Chemother 45: 3276-3278.
14. Maurin M, Raoult D, 1999. Q fever. Clin Microbiol Rev 12: 518-553.